article thumbnail

Reaching New Global ‘Frontiers’ In Life Sciences

Intouch Solutions

The annual event assembled nearly 1,000 attendees from over 40+ countries across the healthcare ecosystem to learn, network and explore industry challenges, strategic trends and solutions in life sciences and healthcare.

article thumbnail

‘Cliff’ Countdown: Balancing Internal and External Growth

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, explores the two major strategies big pharma companies are employing amid current macro challenges and efforts to offset looming patent losses to blockbuster brands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

article thumbnail

ODAIA wins $25m funding to boost commercial insights platform for pharma

Pharmaceutical Technology

ODAIA, a life sciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by life science brands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. Analysing the world of digitally-native brands highlights three standout ways in which parts of their approach could be brought to the pharmaceutical world. Be more agile .

Branding 114
article thumbnail

Changes to UK Statutory Scheme go ahead despite pharma criticism

Drug Discovery World

The UK government has published new terms for the Statutory Scheme for branded medicines, which controls the prices of medicines paid by the NHS. This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% in 2024, 24% in 2025 and 26.8% in Spain and 8.25% in Ireland.

article thumbnail

Industry rejects ‘damaging’ changes to UK medicines scheme

Drug Discovery World

Over twenty pharma companies have rejected the UK government’s proposed changes to the statutory scheme for branded medicines, the latest move in an ongoing disagreement between the government and industry. And will be “highly damaging to UK life sciences and NHS patients’ access to medicines”.